ACCORD-UK LTD

Manufacture of pharmaceutical preparations

Information

Name

ACCORD-UK LTD

Type

Manufacture of pharmaceutical preparations

Roles

Supplier

Company Size

Large

Company Number

00079585

Incorporation Date

1903-12-30 00:00:00

Website

https://etendersni.gov.uk/epps

Address

Barnstaple

United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with ACCORD-UK LTD
Sign up free

Contracts awarded to ACCORD-UK LTD

The contracts that ACCORD-UK LTD have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 3 weeks ago

Generic, Branded Generic & Proprietary Medicinal Products - Group 16

Generic, Branded Generic & Proprietary Medicinal Products - Group 16 (5762100)

£36,914,657
Award

Published 3 weeks ago

NP30925 Psychiatry and Neurology Medicines

Supply of psychiatry and neurology medicines to NHS Scotland.

£7,031,939
Award

Published 1 month ago

NHS National Generic Pharmaceuticals Wave 15b

NHS National Pharmaceuticals Generic Products – Wave 15b Offer reference number: CM/PHG/23/5698 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/23/5698/01 – Orals (plus non-parenteral) Products CESW: (Midlands and Southwest): 1st October 2025 to 31st May 2027 (20 months) NWLN: (Northwest and London North): 1st October 2025 to 31st May 2027 (20 months) LSNE: (London South and Northeast): 1st October 2025 to 31st May 2027 (20 months) CM/PHG/23/5698/02 – Hospital Only Products DCE (Midlands) & DSW (Southwest): 1st October 2025 to 30th September 2027 (24 months) CM/PHG/23/5698/03 – Hospital Only (Housekeeping) Products DLS (London South) & DNE (Northeast): 1st October 2025 to 31st May 2026 (8 months) DNW (Northwest) & DLN (London North): 1st October 2025 to 31st January 2027 (16 months) DCE (Midlands) & DSW (Southwest): 1st October 2025 to 31st May 2026 (8 months)

£147
Award

Published 1 month ago

NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

£4,108,145,000 Bids close: 5 months ago
Award

Published 1 month ago

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026

£24
Award

Published 1 month ago

NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National

NHS Framework Agreement for Branded Medicines - Tranche A London and South of England and Adult Influenza (National) - 01 September 2025 Offer reference number: CM/PHR/24/5718 CM/PHR/24/5718/01 - NHS Framework Agreement for Branded Medicines - Tranche A for London and South of England. Period of Framework Agreement: 01 September 2025 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/24/5718/02 - NHS Framework Agreement for Branded Medicines - Adult Influenza (National). Period of Framework Agreement: 01 September 2025 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months.

£261,895,933 Bids close: 5 months ago

Contacts

+44 7919830195

[email protected]

+44 7919830195

View all 3 contacts, free!

Statistics (1 Year)

Contracts Won

Total Won

£546,539,586

Average Win

£78,077,084

ACCORD-UK LTD

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to ACCORD-UK LTD

Generic, Branded Generic & Proprietary Medicinal Products - Group 16

NP30925 Psychiatry and Neurology Medicines

NHS National Generic Pharmaceuticals Wave 15b

NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win